| Name | Title | Contact Details |
|---|
Established in 1946, OMRF is an independent, nonprofit biomedical research institute with more than 450 staff and over 50 labs studying cancer, heart disease, autoimmune disorders, and diseases of aging. Breakthroughs in our labs have led to three FDA-approved drugs, including the first targeted therapy approved in the U.S. for sickle cell disease and the first approved treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease. OMRF`s critical research is helping people live longer, healthier lives, one discovery at a time. Along the way, OMRF has garnered worldwide media attention, from leading scientific publications like The New England Journal of Medicine and Science to The New York Times and The Wall Street Journal. By pushing the boundaries of biomedical science, our researchers are helping to win the war against human disease, one discovery at a time.
Dallas Endoscopy Center is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trusted by more than 50,000 customers, Briggs has been helping health care providers improve clinical and financial performance through a wide array of products for more than 60 years.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
Select from over 12,000 Chinese herbs and nutritional supplements including doctor trusted brands * Discounts up to 25% * Free 15 minute consultations available